Trials / Completed
CompletedNCT04305275
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Sage Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy of SAGE-324 compared to placebo on upper limb (UL) tremor reduction in individuals with essential tremor (ET).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-324 | SAGE-324 oral tablet |
| DRUG | SAGE-324 Placebo | SAGE-324 matched placebo oral tablet |
Timeline
- Start date
- 2020-05-19
- Primary completion
- 2021-02-01
- Completion
- 2021-02-15
- First posted
- 2020-03-12
- Last updated
- 2024-04-17
- Results posted
- 2024-04-17
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04305275. Inclusion in this directory is not an endorsement.